The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R
- 1 February 2002
- journal article
- Published by Elsevier in Seminars in Oncology
- Vol. 29 (1) , 41-47
- https://doi.org/10.1053/sonc.2002.30151
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Reversal of multidrug resistance in hematological malignanciesBlood Reviews, 1999
- Multidrug Resistance Protein MRP1, Glutathione, and Related EnzymesPublished by Springer Nature ,1999
- Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic DrugsCancer Biotherapy & Radiopharmaceuticals, 1997
- Glutathione S-transferase and glutathione peroxidase are essential in the early stage of Adriamycin resistance before P-glycoprotein overexpression in HOB1 lymphoma cellsCancer Chemotherapy and Pharmacology, 1996
- Checkpoints of dueling dimers foil death wishesCell, 1994
- CD20: a regulator of cell-cycle progression of B lymphocytesImmunology Today, 1994
- Cell cycle control and cancer chemotherapyJournal of Cellular Biochemistry, 1994
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytesEuropean Journal of Immunology, 1986